If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
MORRISVILLE, N.C. and PALO ALTO, Calif., Jan. 30 (HSMN NewsFeed) — Diagnosoft, Inc., an innovator in magnetic resonance (MR) image analysis software that assists in diagnosis, staging and therapeutic monitoring of cardiovascular disease, has unveiled it…
Devices, Radiology, Cardiology
Diagnosoft, magnetic resonance imaging, Strain-encoding
Posts from ‘January, 2009’
Diagnosoft(R) Introduces Its Third MRI Analysis Innovation
New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
Study Published in British Medical Journal Indicates Masimo SET May Also Reduce the Need for Pre-Operative Neonatal Intensive Care and Prevent Long-term Neurological Morbidity IRVINE, Calif., Jan. 30 (HSMN NewsFeed) — Masimo (Nasdaq: MASI ), the inve…
Devices, Monitoring
Masimo, SET pulse oximetry, pulse oximetry
Lilly Announces Senior Leadership Change
Enrique Conterno promoted to president, Lilly USA, LLC Deirdre Connelly resigns from Lilly to pursue other opportunities INDIANAPOLIS, Jan. Thirty (HSMN NewsFeed) — Eli Lilly and Company (NYSE: LLY ) today announced that Enrique Conterno, currently se…
Biopharmaceuticals, Personnel
Eli Lilly
Nektar Announces Retirement of Irwin Lerner from Board of Directors
SAN CARLOS, Calif., Jan. 29 (HSMN NewsFeed) — Nektar Therapeutics (Nasdaq: NKTR ) announced today that Irwin Lerner has retired from its Board of Directors effective January 23, 2009. Mr. Lerner, former Chairman of Hoffmann-La Roche Inc., has been a mem…
Biopharmaceuticals, Personnel
Nektar Therapeutics
Savient Announces FDA’s Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
EAST BRUNSWICK, N.J., Jan. 28 (HSMN NewsFeed) — Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that its biologics license application (BLA) for pegloticase for treatment-failure gout will be reviewed by the Arthritis Advisory Committee ap…
Biopharmaceuticals, FDA
Savient Pharmaceuticals, pegloticase, urate oxidase, gout
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
PARIS (France), 28 January 2009 - (HSMN NewsFeed) - Ipsen (Euronext:IPN) announced today that it has signed an agreement with Novartis for the co-promotion in France of the antihypertensive drug Exforge®. Already in partnership with Novartis since 2003…
Biopharmaceuticals
Ipsen, Novartis, Exforge, Nisis , Nisisco
The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company
Erik Engelson and Jeff Grainger Join Big Clinical laboratory Device Company Incubator MENLO PARK, Calif., Jan. 28 (HSMN NewsFeed) — The Foundry, LLC, a top clinical device company incubator, announced today that it has completed a $5M Series A financing f…
Devices, Venture Capital, Personnel
Split Rock Senior partners, The Foundry
Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
Product is Japan’s first second-generation drug-eluting stent NATICK, Mass., Jan. 28 (HSMN NewsFeed) — Boston Scientific Corporation (NYSE: BSX ) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (M…
Devices, Interventional Cardiology, Regulatory
Boston Scientific, TAXUS Liberte, Paclitaxel, drug eluting stent
New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
BALTIMORE, Jan. 27 (HSMN NewsFeed) — Most Americans know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional cardiologist and Director of the Sinai Center for…
Devices, Interventional Cardiology
coronary stent, platelet aggregation, clopidogrel
Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbott s Architect(R) Analyzers
Test may help physicians identify effective treatment earlier MALVERN, Pennsylvania and ABBOTT PARK, Illinois, January 27 (HSMN NewsFeed) — Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop a new ovarian cancer test fo…
Diagnostics, Oncology
Fujirebio Diagnostics, Abbott, HE4 biomarker, ovarian cancer
